

CITATION REPORT

List of articles citing

Amiodarone pharmacokinetics

DOI: 10.1016/0002-8703(83)90006-6
American Heart Journal, 1983, 106, 840-7.

Source: <https://exaly.com/paper-pdf/16389603/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
400	AMIODARONE - WHEN AND FOR WHOM?. 1983 , 322, 1123-1124		
399	Side effects and possible contraindications of amiodarone use. <i>American Heart Journal</i> , 1983 , 106, 916-23	4.9	123
398	Efficacy and safety of long-term amiodarone in treatment of cardiac arrhythmias: dosage experience. <i>American Heart Journal</i> , 1983 , 106, 935-43	4.9	95
397	Amiodarone dosing: a proposal based on its pharmacokinetics. <i>American Heart Journal</i> , 1983 , 106, 951-6	4.9	76
396	Amiodarone: the experience of the past decade. 1983 , 287, 1654-6		28
395	The QT interval: a predictor of the plasma and myocardial concentrations of amiodarone. 1984 , 51, 316-20		58
394	Management of cardiac drug overdose. 1984 , 11, 207-16		3
393	Bioavailability of amiodarone. <i>European Journal of Clinical Pharmacology</i> , 1984 , 26, 533-4	2.8	6
392	Amiodarone disposition: polyexponential, power and gamma functions. <i>European Journal of Clinical Pharmacology</i> , 1984 , 26, 655-6	2.8	23
391	Amiodarone kinetics after single i.v. bolus and multiple dosing in healthy volunteers. <i>European Journal of Clinical Pharmacology</i> , 1984 , 27, 491-4	2.8	17
390	Clinical pharmacology of amiodarone. 1984 , 427, 112-26		5
389	Amiodarone: electrophysiologic actions, pharmacokinetics and clinical effects. 1984 , 3, 1059-71		194
388	Tissue extraction of amiodarone and N-desethylamiodarone in man after a single oral dose. 1984 , 18, 759-63		15
387	Clinical pharmacokinetics of the newer antiarrhythmic agents. 1984 , 9, 375-403		45
386	Amiodarone for long-term management of patients with hypertrophic cardiomyopathy. 1984 , 54, 802-10		100
385	Amiodarone: prolonged elimination following cessation of chronic therapy. <i>American Heart Journal</i> , 1984 , 107, 787-8	4.9	14
384	Clinical pharmacokinetics of amiodarone. 1984 , 9, 136-56		218

383	Clinical use and pharmacology of amiodarone. 1984 , 68, 1339-66		31
382	Neuropathy and fatal hepatitis in a patient receiving amiodarone. 1984 , 288, 1638-9		34
381	Steady-state serum amiodarone concentrations: relationships with antiarrhythmic efficacy and toxicity. 1984 , 101, 462-9		157
380	Disabling neurological complications of amiodarone. 1985 , 15, 300-4		23
379	Pharmacokinetics of amiodarone, desethylamiodarone and other iodine-containing amiodarone metabolites. <i>European Journal of Clinical Pharmacology</i> , 1985 , 29, 417-23	2.8	25
378	Anaesthesia and amiodarone. 1985 , 32, 629-38		39
377	Amiodarone-treated patients with suppressed TSH test are at risk of thyrotoxicosis. 1985 , 63, 168-75		17
376	Amiodarone and desethylamiodarone elimination kinetics following withdrawal of long-term amiodarone maintenance therapy. 1985 , 6, 209-15		19
375	Tissue-serum correlates of digoxin-amiodarone pharmacokinetic interaction in rats: evidence for selective tissue accumulation and reduced tissue binding. 1985 , 74, 1067-70		6
374	Antiarrhythmic drug therapy (Part 2). Benefits and hazards. <i>Chest</i> , 1985 , 88, 618-24	5.3	10
373	The pathology of amiodarone neurotoxicity. I. Experimental studies with reference to changes in other tissues. 1985 , 108 (Pt 3), 735-52		31
372	Use of amiodarone and digoxin specific Fab antibodies in digoxin overdosage. 1985 , 53, 462-4		2
371	Amiodarone and its desethyl metabolite: tissue distribution and morphologic changes during long-term therapy. <i>Circulation</i> , 1985 , 72, 1064-75	16.7	144
370	Amiodarone: pharmacology and antiarrhythmic and adverse effects. 1985 , 5, 298-313		44
369	Kinetics of electrophysiologic changes during oral loading of amiodarone and after withdrawal of amiodarone in the unsedated dog. <i>Circulation</i> , 1985 , 72, 1380-5	16.7	6
368	An open comparison of amiodarone with diltiazem and glyceryl trinitrate in patients with stable exertional angina. 1985 , 29 Suppl 3, 31-6		4
367	Amiodarone treatment in patients with ventricular arrhythmias. 1985 , 29 Suppl 3, 47-52		7
366	Absolute bioavailability of amiodarone in normal subjects. 1985 , 37, 118-23		43

365	Important differences between short- and long-term hemodynamic effects of amiodarone in patients with chronic ischemic heart disease at rest and during ischemia-induced left ventricular dysfunction. 1985 , 5, 1205-11		47
364	Pneumonitis with pleural and pericardial effusion and neuropathy during amiodarone therapy. <i>International Journal of Cardiology</i> , 1985 , 8, 81-8	3.2	11
363	[Delayed neuropathy caused by amiodarone hydrochloride]. <i>Revue De Medecine Interne</i> , 1985 , 6, 303-6	0.1	
362	Hyperthyroidism with a low iodine uptake. 1985 , 14, 397-415		6
361	Intravenous and oral loading versus oral loading alone with amiodarone for chronic refractory ventricular arrhythmias. 1985 , 55, 89-91		36
360	Amiodarone in pregnancy. 1985 , 56, 196-7		19
359	Evaluation by serial electrophysiologic studies of an abbreviated oral loading regimen of amiodarone. 1985 , 56, 867-71		21
358	Electropharmacology of amiodarone: absence of relationship to serum, myocardial, and cardiac sarcolemmal membrane drug concentrations. <i>American Heart Journal</i> , 1986 , 112, 916-22	4.9	24
357	Amiodarone-associated changes in human neutrophils. 1986 , 57, 666-72		15
356	Effects of congestive heart failure on the pharmacokinetics and pharmacodynamics of antiarrhythmic agents. 1986 , 57, 25B-33B		42
355	Amiodarone, thyroid hormone indexes, and altered thyroid function: long-term serial effects in patients with cardiac arrhythmias. 1986 , 58, 981-6		54
354	Peripheral neutrophil inclusions in amiodarone treated patients. 1986 , 22, 736-8		16
353	Amiodarone and desethylamiodarone distribution in the atrium and adipose tissue of patients undergoing short- and long-term treatment with amiodarone. 1986 , 8, 210-3		31
352	Comparative antiarrhythmic efficacy of verapamil, 17-monochloroacetylajmaline, mexiletine and amiodarone in patients with severe chagasic myocarditis: relation with the underlying arrhythmogenic mechanisms. 1986 , 7, 1114-20		19
351	Flecainide and amiodarone interaction. 1986 , 7, 1127-30		55
350	Atrioventricular block complicating amiodarone-induced hypothyroidism in a patient with pre-excitation and rate-dependent bilateral bundle branch block. 1986 , 7, 180-4		8
349	Myocardial uptake of drugs and clinical effects. 1986 , 11, 354-71		20
348	Effects of amiodarone and desethylamiodarone on pituitary deiodinase activity and thyrotropin secretion in the rat. 1986 , 292, 136-41		26

347	Amiodarone Pulmonary Toxicity: Clinical and Subclinical Features. 1986 ,		
346	Effect of renal failure or biliary stasis on the pharmacokinetics of amiodarone in the rat. 1986 , 75, 150-4		9
345	Amiodarone, phaeochromocytoma and cardiomyopathy. 1986 , 41, 186-90		8
344	Hemodynamic Effects of Amiodarone. 1986 , 4, 491-498		
343	The effect of amiodarone on theophylline pharmacokinetics in the rat. 1986 , 3, 167-9		5
342	Amiodarone: an effective alternative for recalcitrant supraventricular and ventricular tachycardias. 1986 , 9, 268-71		2
341	Relapsing Fisher's syndrome. 1986 , 49, 604-6		8
340	Pseudotumor cerebri with amiodarone. 1986 , 49, 606		17
339	Adult onset spinal muscular atrophy with atrophic testes: report of two cases. 1986 , 49, 606-8		5
338	Intravenous and oral amiodarone for arrhythmias in children. 1986 , 56, 278-84		40
337	Amiodarone. 1987 , 317, 451-4		1
336	Clinical, haemodynamic, and antiarrhythmic effects of long term treatment with amiodarone of patients in heart failure. 1987 , 57, 436-45		85
335	Comparative electrophysiologic effects of intravenous amiodarone and desethylamiodarone in dogs: evidence for clinically relevant activity of the metabolite. <i>Circulation</i> , 1987 , 75, 265-71	16.7	76
334	Amiodarone induced phospholipidosis. Biochemical, morphological and functional changes in the lungs of rats chronically treated with amiodarone. 1987 , 36, 3209-14		33
333	Increase in renal cytochrome P-450 and NADPH cytochrome c reductase activity following drug inhibition of hepatic monooxygenase activity. 1987 , 36, 768-9		7
332	Relationship of steady-state serum concentrations of amiodarone and desethylamiodarone to therapeutic efficacy and adverse effects. 1987 , 82, 1102-8		35
331	Effects of acute intravenous and chronic oral amiodarone on defibrillation energy requirements. <i>American Heart Journal</i> , 1987 , 114, 8-17	4.9	86
330	Amiodarone efficacy in a young population: relationship to serum amiodarone and desethylamiodarone levels. <i>American Heart Journal</i> , 1987 , 114, 283-7	4.9	30

329	Interaction of amiodarone and desethylamiodarone with solubilized nuclear thyroid hormone receptors. 1987 , 9, 872-6		62
328	Relation between amiodarone and desethylamiodarone plasma concentrations and electrophysiologic effects, efficacy and toxicity. 1987 , 9, 1148-55		53
327	Resting, and rate-dependent depression of Vmax of guinea-pig ventricular action potentials by amiodarone and desethylamiodarone. 1987 , 92, 97-103		29
326	Effects of amiodarone and thyroid dysfunction on myocardial calcium, serum calcium and thyroid hormones in the rat. 1987 , 92, 363-70		
325	Multiple chalazia and rosacea in a patient treated with amiodarone. 1987 , 103, 594-5		15
324	Amiodarone. 1987 , 316, 455-66		430
323	Renal Considerations in Cardiovascular Drug Therapy. 1987 , 5, 675-688		4
322	Amiodarone and the Thyroid. 1987 ,		
321	Rapid high-performance liquid chromatographic method for the determination of amiodarone and desethylamiodarone in human plasma and serum. 1987 , 415, 197-202		12
320	Effect of amiodarone on serum T4 and T3 levels in hyperthyroid patients treated with methimazole. <i>European Journal of Clinical Pharmacology</i> , 1987 , 32, 223-7	2.8	8
319	Amiodarone pharmacokinetics. II. Disposition kinetics following subchronic administration in rats. 1987 , 8, 449-60		4
318	Sensitive method for the measurement of amiodarone and desethylamiodarone in serum and tissue and its application to disposition studies. 1987 , 385, 225-32		16
317	Electrophysiologic predictors of long-term clinical outcome with amiodarone for refractory ventricular tachycardia secondary to coronary artery disease. 1987 , 60, 293-7		27
316	Amiodarone and digoxin for refractory fetal tachycardia. 1987 , 59, 166-7		58
315	Dynamical dosage regimen calculations in linear pharmacokinetics. 1988 , 21, 203-20		10
314	Effect on growth of children with cardiac dysrhythmias treated with amiodarone. <i>Pediatric Cardiology</i> , 1988 , 9, 33-6	2.1	11
313	Implanted automatic defibrillators: effects of drugs and pacemakers. 1988 , 11, 2250-62		54
312	Amiodarone pharmacokinetics in coronary patients: differences between acute and one-month chronic dosing. 1988 , 13, 67-72		5

311	Concentration response relationships of amiodarone and desethylamiodarone. <i>American Heart Journal</i> , 1988 , 115, 1208-13	4.9	17
310	Electrophysiologic effects of desethylamiodarone, an active metabolite of amiodarone: comparison with amiodarone during chronic administration in rabbits. <i>American Heart Journal</i> , 1988 , 115, 351-9	4.9	44
309	New antiarrhythmic drugs. 1988 , 35, 286-319		23
308	Recent advances in understanding the pharmacology of amiodarone. 1988 , 36, 121-31		38
307	The reversal of amiodarone-induced perioperative reduction in cardiac systolic reserve in dogs. 1988 , 12, 757-64		13
306	Use of intravenous amiodarone for emergency treatment of life-threatening ventricular arrhythmias. 1988 , 12, 1015-22		80
305	Plasma protein binding of amiodarone in a patient population: measurement by erythrocyte partitioning and a novel glass-binding method. 1988 , 26, 721-31		24
304	Haemodynamic effects of short term intravenous amiodarone for hypertrophic cardiomyopathy. 1988 , 59, 446-52		2
303	Amiodarone therapeutic plasma concentration monitoring. Is it practical?. 1988 , 14, 321-4		6
302	Atenolol and amiodarone: a comparative study of their anti-ischæmic effect. 1988 , 16, 114-24		2
301	Amiodarone in the management of cardiac arrhythmias: current concepts. 1988 , 72, 321-58		17
300	Amiodarone pulmonary toxicity. Recognition and pathogenesis (Part 2). <i>Chest</i> , 1988 , 93, 1242-8	5.3	121
299	Possible interference by amiodarone and desethylamiodarone in thyroxin assays.. 1988 , 34, 2154-2154		
298	Intra-erythrocytic Mg assay in the Kodak Ektachem 700 analyzer.. 1988 , 34, 2154-2155		3
297	Chicken egg yolk and rabbit serum compared as sources of antibody for radioimmunoassay of 1,25-dihydroxyvitamin D in serum or plasma.. 1988 , 34, 2153-2154		11
296	The relevance of pharmacokinetics to monitoring new antiarrhythmics.. 1989 , 35, 1332-1336		2
295	Management of Arrhythmias in Heart Failure. 1989 , 7, 145-169		14
294	Electropharmacology of amiodarone therapy initiation. Time courses of onset of electrophysiologic and antiarrhythmic effects. <i>Circulation</i> , 1989 , 80, 34-42	16.7	80

293	Amiodarone and desethylamiodarone toxicity in isolated hepatocytes in culture. 1989 , 190, 163-9		23
292	Rate-related electrophysiologic effects of long-term administration of amiodarone on canine ventricular myocardium in vivo. <i>Circulation</i> , 1989 , 79, 948-58	16.7	71
291	A general overview of amiodarone toxicity: its prevention, detection, and management. 1989 , 31, 393-426		91
290	Efficacy and toxicity of amiodarone for the treatment of supraventricular tachyarrhythmias. 1989 , 31, 355-66		38
289	The historical development, cellular electrophysiology and pharmacology of amiodarone. 1989 , 31, 249-80		95
288	The use of intravenous amiodarone in the acute therapy of life-threatening tachyarrhythmias. 1989 , 31, 281-94		28
287	Pulmonary fibrosis induced in the hamster by amiodarone and desethylamiodarone. <i>Toxicology and Applied Pharmacology</i> , 1989 , 100, 350-9	4.6	35
286	Amiodarone is a potent calmodulin antagonist. 1989 , 339, 367-73		15
285	Effects of amiodarone on the kinetics of antipyrine. 1989 , 63, 991-2		2
284	Effect of age on antiarrhythmic drug efficacy and toxicity. 1989 , 63, 735-9		11
283	Correlation of amiodarone dosage, heart rate, QT interval and corneal microdeposits with serum amiodarone and desethylamiodarone concentrations. 1989 , 64, 1138-43		28
282	Inhibition of calmodulin and protein kinase C by amiodarone and other class III antiarrhythmic agents. 1989 , 3, 675-82		16
281	Amiodarone hepatotoxicity: prevalence and clinicopathologic correlations among 104 patients. 1989 , 9, 679-85		202
280	Pharmacokinetic interaction between diltiazem and amiodarone in the dog. 1989 , 10, 423-9		3
279	Amiodarone-induced complications after cardiac operation for obstructive hypertrophic cardiomyopathy. 1989 , 48, 359-64		28
278	Clinical pharmacokinetic considerations in the elderly. An update. 1989 , 17, 236-63		100
277	Cytotoxic effects of amiodarone and desethylamiodarone on human thyrocytes. 1989 , 38, 4397-403		46
276	Long-term efficacy and toxicity of high- and low-dose amiodarone regimens. 1989 , 29, 418-23		25

275	Basic and clinical pharmacology of amiodarone: relationship of antiarrhythmic effects, dose and drug concentrations to intracellular inclusion bodies. 1989 , 29, 405-12		32
274	Acute necrotising myopathy associated with amiodarone therapy. 1989 , 19, 483-5		21
273	Intestinal absorption of amiodarone in man. 1990 , 30, 615-20		7
272	Amiodarone: a postmarketing evaluation of monitoring for drug-induced toxicity. 1990 , 24, 1001-6		3
271	Efficacy and tolerance of high-dose intravenous amiodarone for recurrent, refractory ventricular tachycardia. 1990 , 65, 609-14		50
270	Advances in oral anti-arrhythmic therapy: implications for the anaesthetist. 1990 , 37, 94-101		8
269	Stability of plasma amiodarone levels during chronic oral therapy. 1990 , 4, 529-30		4
268	Amiodarone reduces the effect of T3 on beta adrenergic receptor density in rat heart. 1990 , 22, 85-9		32
267	Effect of phenytoin on the clinical pharmacokinetics of amiodarone. 1990 , 30, 1112-9		19
266	Risk-benefit assessment of amiodarone in the treatment of cardiac arrhythmias. 1990 , 5, 286-304		12
265	Design of toxicokinetic studies. <i>Xenobiotica</i> , 1990 , 20, 1187-99	2	34
264	The effects of plasmapheresis on thyroid hormone and plasma drug concentrations in amiodarone-induced thyrotoxicosis. 1991 , 31, 371-2		26
263	Relationship between myocardial amiodarone concentration and antiarrhythmic effect in dogs with myocardial infarction and electrically induced ventricular arrhythmias. <i>Canadian Journal of Physiology and Pharmacology</i> , 1991 , 69, 812-7	2.4	3
262	Side effects from amiodarone. <i>American Heart Journal</i> , 1991 , 121, 158-71	4.9	110
261	An increase in plasma cholesterol independent of thyroid function during long-term amiodarone therapy. A dose-dependent relationship. 1991 , 114, 128-32		15
260	Iodine-131 treatment of hyperthyroidism: current issues. 1991 , 35, 207-12		61
259	QT-interval prolonging drugs: mechanisms and clinical relevance of their arrhythmogenic hazards. 1991 , 5, 515-30		67
258	Analytical Profile of Amiodarone. 1991 , 1-120		3

257	Pharmacology and pharmacokinetics of amiodarone. 1991 , 31, 1061-9		73
256	Rapid Microdetermination of Amiodarone and its Metabolite N. Desethylamiodarone in Plasma by High-Performance Liquid Chromatography. 1991 , 24, 603-623		12
255	Chylous transport of amiodarone. <i>Chest</i> , 1992 , 101, 573-4	5.3	8
254	Amiodarone pulmonary toxicity. 1992 , 303, 206-12		29
253	Advances in antiarrhythmic drug therapy. 1992 , 23, 179-225		1
252	Amiodarone: Pharmacology, Clinical Actions, and Relationships Between Them. <i>Journal of Cardiovascular Electrophysiology</i> , 1992 , 3, 266-280	2.7	30
251	Amiodarone. An overview of its pharmacological properties, and review of its therapeutic use in cardiac arrhythmias. 1992 , 43, 69-110		118
250	Toxicité neurologique de l'amiodarone. À propos de cinq observations. <i>Revue De Medecine Interne</i> , 1992 , 13, 419-422	0.1	14
249	High dose oral amiodarone loading: electrophysiologic effects and clinical tolerance. 1992 , 19, 169-73		24
248	A comparison of standard and high-dose regimens for the initiation of amiodarone therapy. <i>American Heart Journal</i> , 1992 , 124, 366-73	4.9	4
247	Defibrillation threshold: clinical utility and therapeutic implications. 1992 , 15, 932-49		121
246	High-performance liquid chromatographic assay for amiodarone N-deethylation in microsomes of rat liver. 1992 , 579, 269-76		12
245	Can amiodarone pulmonary toxicity be predicted in patients undergoing implantable cardioverter defibrillator implantation?. 1993 , 16, 2241-9		20
244	Amiodarone and the thyroid: pharmacological, toxic and therapeutic effects. 1993 , 233, 435-43		21
243	Pharmacokinetics of amiodarone: implications for drug therapy. 1993 , 72, 45F-50F		42
242	Cellular accumulation of amiodarone and desethylamiodarone in cultured human cells. Consequences of drug accumulation on cellular lipid metabolism and plasma membrane properties of chronically exposed cells. 1993 , 45, 349-56		29
241	Class III antiarrhythmics in overdose. Presenting features and management principles. 1993 , 9, 450-62		15
240	Intravenous amiodarone for life-threatening tachyarrhythmias in children and young adults. 1993 , 22, 95-8		80

239	Amiodarone pulmonary toxicity: its radiological features. 1993 , 37, 47-9	2
238	Clinical measurement of serum amiodarone and desethylamiodarone by using solid-phase extraction followed by HPLC with a high-carbon reversed-phase column. 1993 , 39, 496-500	14
237	Carbamazepine kinetics in cardiac patients before and during amiodarone. 1994 , 52, 210-5	4
236	Side effects with amiodarone therapy. 1994 , 70, 492-8	24
235	Effects of surfactants on amiodarone intestinal absorption. I. Sodium laurylsulfate. 1994 , 11, 1042-7	6
234	Response to sotalol predicts the response to amiodarone during serial drug testing in patients with sustained ventricular tachycardia and coronary artery disease. 1994 , 73, 357-60	3
233	Amiodarone-induced vasculitis and a review of the cutaneous side-effects of amiodarone. 1994 , 19, 422-4	20
232	Effects of amiodarone on refractory ventricular fibrillation in acute myocardial infarction: experimental study. 1994 , 23, 253-8	34
231	Conduction disturbances after open heart operation in a patient receiving amiodarone. 1994 , 58, 1213-4	5
230	Is there a link between the phototoxic or antioxidant properties of amiodarone, an antiarrhythmic drug, and its lipophilic character?. 1994 , 48, 851-7	8
229	Acute treatment of recent-onset atrial fibrillation and flutter with a tailored dosing regimen of intravenous amiodarone. A randomized, digoxin-controlled study. 1995 , 16, 521-8	143
228	Additive cardiac depression by volatile anesthetics in isolated hearts after chronic amiodarone treatment. 1995 , 80, 917-24	1
227	Additive Cardiac Depression by Volatile Anesthetics in Isolated Hearts After Chronic Amiodarone Treatment. 1995 , 80, 917-924	3
226	Differences in amiodarone, digoxin, flecainide and sotalol concentrations between antemortem serum and femoral postmortem blood. 1995 , 14, 605-8	18
225	Prediction of electrophysiologic study results in patients treated with amiodarone. <i>American Heart Journal</i> , 1995 , 129, 496-501	4-9
224	Effect of amiodarone therapy on mortality in patients with left ventricular dysfunction and asymptomatic complex ventricular arrhythmias: Argentine Pilot Study of Sudden Death and Amiodarone (EPAMSA). <i>American Heart Journal</i> , 1995 , 130, 494-500	4-9 63
223	Pregnancy outcome after gestational exposure to amiodarone in Canada. 1995 , 172, 1307-11	103
222	Intravenous amiodarone for recurrent sustained hypotensive ventricular tachyarrhythmias. Intravenous Amiodarone Multicenter Trial Group. 1996 , 27, 67-75	148

221	Pharmacokinetics of intravenous amiodarone in patients with impaired left ventricular function. 1996 , 36, 720-7		9
220	Disposition of intravenous amiodarone in subjects with normal and impaired renal function. 1996 , 36, 122-30		14
219	Intravenous amiodarone: pharmacology, pharmacokinetics, and clinical use. 1996 , 30, 637-43		52
218	Induction of ventricular fibrillation predicts sudden death in patients treated with amiodarone because of ventricular tachyarrhythmias after a myocardial infarction. 1996 , 75, 23-8		5
217	Cationic amphiphilic drug-induced phospholipidosis. 1997 , 25, 53-60		282
216	Population pharmacokinetics of intravenous amiodarone and comparison with two-stage pharmacokinetic analysis. 1997 , 37, 610-7		20
215	Intravenous amiodarone. 1997 , 29, 1190-8		87
214	Adverse effects of low dose amiodarone: a meta-analysis. 1997 , 30, 791-8		319
213	Suggested Transition from Oral to Intravenous Amiodarone Therapy. 1997 , 13, 72-74		
212	Chronic amiodarone reduces transmural dispersion of repolarization in the canine heart. <i>Journal of Cardiovascular Electrophysiology</i> , 1997 , 8, 1269-79	2.7	130
211	Pharmacologic and pharmacokinetic profile of class III antiarrhythmic drugs. 1997 , 80, 16G-23G		28
210	Efficacy, safety, and determinants of conversion of atrial fibrillation and flutter with oral amiodarone. 1997 , 79, 53-7		92
209	Intestinal absorption kinetics of amiodarone in rat small intestine. 1997 , 18, 523-32		11
208	Time course of myocardial amiodarone uptake in the piglet heart using a chronic animal model. <i>Pediatric Cardiology</i> , 1998 , 19, 204-11	2.1	9
207	The Science and Practice of Pediatric Cardiology. <i>Pediatric Cardiology</i> , 1998 , 19, 211	2.1	2
206	Adverse effects of amiodarone. 1998 , 21, 108-20		53
205	Myocardial amiodarone concentrations after short- and long-term treatment in patients with end-stage heart failure. <i>European Journal of Clinical Pharmacology</i> , 1998 , 53, 331-6	2.8	27
204	Therapeutic drug monitoring: antiarrhythmic drugs. 1998 , 46, 307-19		53

203	Development of severe adverse effects after discontinuing amiodarone therapy in human heart transplant recipients. 1998 , 30, 3943-4		5
202	Bilateral anterior ischaemic optic neuropathy following amiodarone. 1998 , 12 (Pt 5), 894-6		13
201	Investigation of Relatively Rare Adverse Drug Events as Exemplified by a Study of Amiodarone-Induced Optic Neuropathy. 1998 , 15, 1-16		3
200	A case report of myolysis during high-dose amiodarone therapy for uncontrolled ventricular tachycardia. 1998 , 62, 305-8		1
199	Evidence-based analysis of amiodarone efficacy and safety. <i>Circulation</i> , 1999 , 100, 2025-34	16.7	240
198	Optic neuropathy following amiodarone therapy. 1999 , 22, 1108-10		12
197	The anomalous pharmacokinetics of amiodarone explained by nonexponential tissue trapping. 1999 , 27, 383-96		38
196	Amiodarone concentration in human myocardium after rapid intravenous administration. 1999 , 13, 265-70		10
195	Mechanisms underlying variability in response to drug therapy: implications for amiodarone use. 1999 , 84, 29R-36R		14
194	Clinical organ toxicity of antiarrhythmic compounds: ocular and pulmonary manifestations. 1999 , 84, 37R-45R		149
193	Effect of amiodarone and sotalol on the defibrillation threshold in comparison to patients without antiarrhythmic drug treatment. <i>International Journal of Cardiology</i> , 1999 , 69, 271-9	3.2	34
192	Inhibitory effects of amiodarone and its N-deethylated metabolite on human cytochrome P450 activities: prediction of in vivo drug interactions. 2000 , 49, 244-53		148
191	Dramatic inhibition of amiodarone metabolism induced by grapefruit juice. 2000 , 49, 373-8		67
190	Bone marrow granulomas possibly associated with amiodarone. 2000 , 20, 855-9		6
189	Amiodarone has exclusively non-genomic action on cardiac beta-adrenoceptor regulation. 2000 , 408, 227-32		2
188	Population pharmacokinetics of long-term oral amiodarone therapy. 2000 , 67, 642-52		67
187	Coronary artery bypass graft surgery and phrenic nerve injury: another twist, unilateral amiodarone pulmonary toxicity. 2000 , 11, 153-156		1
186	Amiodarone induces cytochrome c release and apoptosis through an iodine-independent mechanism. 2000 , 85, 4323-30		46

185	Part 10: Pediatric Advanced Life Support. <i>Circulation</i> , 2000 , 102, I-291-I-342	16.7	3
184	Desethylamiodarone interferes with the binding of co-activator GRIP-1 to the beta 1-thyroid hormone receptor. 2000 , 481, 213-6		15
183	Hemodynamic and Electrocardiographic Effects of Graded Doses of Amiodarone in Healthy Dogs Anesthetized with Morphine/Alpha Chloralose. 2000 , 14, 90-95		8
182	Part 10: pediatric advanced life support. European Resuscitation Council. 2000 , 46, 343-99		24
181	Amiodarone stimulates interleukin-6 production in cultured human thyrocytes, exerting cytotoxic effects on thyroid follicles in suspension culture. 2001 , 11, 101-9		22
180	The various effects of amiodarone on thyroid function. 2001 , 11, 511-9		109
179	Effects of amiodarone administration during pregnancy on neonatal thyroid function and subsequent neurodevelopment. <i>Journal of Endocrinological Investigation</i> , 2001 , 24, 116-30	5.2	153
178	Disposition of amiodarone in rats after single and multiple intraperitoneal doses. 2001 , 26, 65-9		8
177	Inhibition of purified pig and human liver retinyl ester hydrolase by pharmacologic agents. 2001 , 36, 543-8		8
176	The role of pharmacologic treatment to prevent sudden death in the implantable cardioverter defibrillator era. 2001 , 3, 167-72		4
175	Amiodaron. 2001 , 38, 169-178		9
174	Antioxidant activity of amiodarone on human lipoprotein oxidation. 2001 , 133, 739-45		12
173	Bioavailability of amiodarone tablets administered with and without food in healthy subjects. 2001 , 87, 432-5		49
172	A review of class III antiarrhythmic agents for atrial fibrillation: maintenance of normal sinus rhythm. 2001 , 21, 1514-29		18
171	[Amiodarone]. 2001 , 126, 625-6		
170	The effects of amiodarone on the thyroid. 2001 , 22, 240-54		304
169	Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases. 2002 , 23, 38-89		1299
168	Drug-induced lupus erythematosus by amiodarone. 2002 , 162, 834-6		21

167	MDR1-mediated interaction of digoxin with antiarrhythmic or antianginal drugs. <i>Biological and Pharmaceutical Bulletin</i> , 2002 , 25, 1604-7	2.3	43
166	Development of an enzyme-linked immunosorbent assay for the quantification of amiodarone. <i>Biological and Pharmaceutical Bulletin</i> , 2002 , 25, 954-8	2.3	7
165	Use of cardiovascular medications in the elderly. <i>International Journal of Cardiology</i> , 2002 , 85, 203-15	3.2	32
164	Amiodarone N-deethylation by CYP2C8 and its variants, CYP2C8*3 and CYP2C8 P404A. 2002 , 91, 174-8		49
163	High-performance liquid chromatographic assay for amiodarone N-deethylation activity in human liver microsomes using solid-phase extraction. 2002 , 774, 105-13		6
162	Organic anion transporter oatp2-mediated interaction between digoxin and amiodarone in the rat liver. 2002 , 19, 738-43		44
161	Combined amiodarone and silymarin treatment, but not amiodarone alone, prevents sustained atrial flutter in dogs. <i>Journal of Cardiovascular Electrophysiology</i> , 2003 , 14, 861-7	2.7	6
160	Potentially significant drug interactions of class III antiarrhythmic drugs. 2003 , 26, 421-38		66
159	Amiodarone Interaction Time Differences with Warfarin and Digoxin. 2003 , 19, 83-90		1
158	Dronerarone acts as a selective inhibitor of 3,5,3'-triiodothyronine binding to thyroid hormone receptor-alpha1: in vitro and in vivo evidence. 2003 , 144, 552-8		65
157	Hepatic necrosis resulting in leak of amiodarone and refractory cardiogenic shock. 2004 , 59, 373-4		
156	Phenylacetylglutamine, a putative biomarker of phospholipidosis: its origins and relevance to phospholipid accumulation using amiodarone treated rats as a model. 2004 , 9, 271-90		76
155	Pharmacokinetics and pharmacodynamic effects of amiodarone in plasma of ponies after single intravenous administration. <i>Toxicology and Applied Pharmacology</i> , 2004 , 195, 113-25	4.6	15
154	Use of population modeling to define rational monitoring of amiodarone hepatic effects. 2004 , 75, 342-51		24
153	La gestione del paziente nella tireotossicosi e nell'ipotiroidismo indotti da amiodarone. 2004 , 5, 31-38		
152	Part 12: Pediatric Advanced Life Support. <i>Circulation</i> , 2005 , 112, IV-167-IV-187	16.7	18
151	Evaluation of the pharmacokinetics and bioavailability of intravenously and orally administered amiodarone in horses. 2006 , 67, 448-54		12
150	Adherence to the NASPE guideline for amiodarone monitoring at a medical university. 2006 , 12, 254-9		21

149	Amiodarone pulmonary toxicity: a patient with three recurrences of pulmonary toxicity and consideration of the probable risk for relapse. 2006 , 45, 1303-7		21
148	Cardiac Dysrhythmias during Donor Care. <i>Progress in Transplantation</i> , 2006 , 16, 74-81	1.1	6
147	Mild and short recurrence of type II amiodarone-induced thyrotoxicosis in three patients receiving amiodarone continuously for more than 10 years. 2006 , 53, 531-8		18
146	Serum amiodarone and desethylamiodarone concentrations following nasogastric versus oral administration. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2006 , 31, 237-43	2.2	16
145	Use of the Broselow tape may result in the underresuscitation of children. 2006 , 13, 1011-9		69
144	Antiarrhythmic drug therapy. 2006 , 8, 362-70		
143	2005 American Heart Association (AHA) guidelines for cardiopulmonary resuscitation (CPR) and emergency cardiovascular care (ECC) of pediatric and neonatal patients: pediatric advanced life support. 2006 , 117, e1005-28		100
142	Antiarrhythmic Medications. 2007 , 3, 33-38		0
141	A fatal case of recurrent amiodarone-induced thyrotoxicosis after percutaneous tracheotomy: a case report. 2007 , 1, 134		1
140	Pharmacology of cardiac arrest and reperfusion. 395-416		
139	In reply. 2007 , 14, 501-502		3
138	Amiodarone prophylaxis for atrial fibrillation after cardiac surgery: meta-analysis of dose response and timing of initiation. 2007 , 27, 360-8		28
137	Simultaneous determination of amiodarone and its metabolite desethylamiodarone by high-performance liquid chromatography with chemiluminescent detection. 2008 , 623, 89-95		6
136	Part IV: Class II, Class III, and Class IV Antiarrhythmic Drugs, Comparative Efficacy of Drugs, and Effect of Drugs on Mortality [A Review of Their Pharmacokinetics, Efficacy, and Toxicity*. <i>Journal of Cardiovascular Electrophysiology</i> , 2008 , 2, 55-87	2.7	
135	Amiodarone inhibits arterial thrombus formation and tissue factor translation. 2008 , 28, 2231-8		20
134	Continuous vs episodic prophylactic treatment with amiodarone for the prevention of atrial fibrillation: a randomized trial. 2008 , 300, 1784-92		55
133	Increased density of the liver and amiodarone-associated phospholipidosis. 2009 , 2009, 598940		10
132	Hepatotoxicity of amiodarone. 1986 , 219, 235-9		16

131	Effect of obesity on serum amiodarone concentration in Japanese patients: population pharmacokinetic investigation by multiple trough screen analysis. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2009 , 34, 329-36	2.2	19
130	Bioequivalence of 2 intravenous amiodarone formulations in healthy participants. 2009 , 49, 407-15		8
129	Contribution of organic anion transporting polypeptide OATP2B1 to amiodarone accumulation in lung epithelial cells. 2009 , 1788, 911-7		35
128	Intrapericardial delivery of amiodarone and sotalol: atrial transmural drug distribution and electrophysiological effects. <i>Journal of Cardiovascular Pharmacology</i> , 2009 , 54, 355-63	3.1	20
127	Amiodarone and thyroid dysfunction. 2010 , 103, 922-30		25
126	Fractional kinetics in multi-compartmental systems. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2010 , 37, 507-24	2.7	67
125	The effect of CYP1A induction on amiodarone disposition in the rat. 2010 , 99, 539-48		6
124	Simultaneous measurement of amiodarone and desethylamiodarone in human plasma and serum by stable isotope dilution liquid chromatography-tandem mass spectrometry assay. 2010 , 51, 210-6		22
123	Amiodarone for the treatment and prevention of ventricular fibrillation and ventricular tachycardia. 2010 , 6, 465-72		37
122	Amiodarone - a 'broad spectrum' antiarrhythmic drug. 2010 , 10, 73-81		23
121	Inhibition of the type 2 iodothyronine deiodinase underlies the elevated plasma TSH associated with amiodarone treatment. 2010 , 151, 5961-70		58
120	The effect of beta-naphthoflavone on the metabolism of amiodarone by hepatic and extra-hepatic microsomes. 2010 , 195, 147-54		20
119	New antiarrhythmic drugs for treatment of atrial fibrillation. 2010 , 375, 1212-23		210
118	Pharmacokinetics in Drug Development. 2011 ,		20
117	Effect of phenobarbitone on the pharmacokinetics and tissue levels of amiodarone in the rat. 1985 , 37, 729-31		9
116	Drug Transporters. <i>Handbook of Experimental Pharmacology</i> , 2011 ,	3.2	13
115	Epicardial application of an amiodarone-releasing hydrogel to suppress atrial tachyarrhythmias. <i>International Journal of Cardiology</i> , 2011 , 149, 341-6	3.2	13
114	Amiodarone-induced pulmonary toxicity. 2011 , 1, 6		

113	Modulators of very low voriconazole concentrations in routine therapeutic drug monitoring. 2011 , 33, 86-93		54
112	The inhibitory effect of amiodarone and desethylamiodarone on dextromethorphan O-demethylation in human and rat liver microsomes. 1994 , 46, 933-5		7
111	Influence of CYP2C8*13 and CYP2C8*14 alleles on amiodarone N-deethylation. 2011 , 108, 359-62		8
110	The ability of polycyclic aromatic hydrocarbons to alter physiological factors underlying drug disposition. 2011 , 43, 457-75		13
109	Population pharmacokinetic investigation for optimization of amiodarone therapy in Japanese patients. 2011 , 33, 750-6		8
108	In vivo probes of drug transport: commonly used probe drugs to assess function of intestinal P-glycoprotein (ABCB1) in humans. <i>Handbook of Experimental Pharmacology</i> , 2011 , 403-47	3.2	23
107	Torsade de Pointes and Persistent QTc Prolongation after Intravenous Amiodarone. 2012 , 2012, 673019		4
106	Comparative bioavailability of a premixed, ready-to-use formulation of intravenous amiodarone with traditional admixture in healthy subjects. 2012 , 52, 214-21		5
105	Action of specific thyroid hormone receptor α 1 and β 1 antagonists in the central and peripheral regulation of thyroid hormone metabolism in the rat. 2012 , 22, 1275-82		12
104	Amiodarone-associated optic neuropathy: a critical review. 2012 , 125, 447-53		51
103	Benefit-risk assessment of dronedarone in the treatment of atrial fibrillation. 2013 , 36, 93-110		8
102	How to avoid unbounded drug accumulation with fractional pharmacokinetics. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2013 , 40, 691-700	2.7	18
101	Amiodarone inhibits tissue factor expression in monocytic THP-1 cells. 2013 , 701, 14-9		
100	Amiodarone-induced thyrotoxicosis late after amiodarone withdrawal. <i>Circulation Journal</i> , 2013 , 77, 2898-903		10
99	Successful treatment of severe amiodarone pulmonary toxicity with polymyxin B-immobilized fiber column direct hemoperfusion. <i>Chest</i> , 2013 , 143, 1146-1150	5.3	12
98	Amiodarone and concurrent antiretroviral therapy: a case report and review of the literature. <i>Antiviral Therapy</i> , 2014 , 19, 329-39	1.6	8
97	Management of atrial fibrillation in critically ill patients. <i>Critical Care Research and Practice</i> , 2014 , 2014, 840615	1.5	31
96	A novel amiodarone-eluting biological glue for reducing postoperative atrial fibrillation: first animal trial. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2014 , 19, 481-91	2.6	5

95	Amiodarone toxicity showing high liver density on CT scan with normal liver function and plasma amiodarone levels in a long-term amiodarone user. <i>International Journal of Cardiology</i> , 2014 , 172, 494-5	3.2	13
94	Continuous intravenous antiarrhythmic agents in the intensive care unit: strategies for safe and effective use of amiodarone, lidocaine, and procainamide. <i>Critical Care Nursing Quarterly</i> , 2015 , 38, 329-44		6
93	Amiodarone-induced lupus-like syndrome. <i>American Journal of Therapeutics</i> , 2015 , 22, e20-1	1	3
92	Physiologically based pharmacokinetic modeling to predict drug-drug interactions involving inhibitory metabolite: a case study of amiodarone. <i>Drug Metabolism and Disposition</i> , 2015 , 43, 182-9	4	39
91	Fractional Pharmacokinetics. <i>Interdisciplinary Applied Mathematics</i> , 2016 , 211-225	0.7	
90	Modeling in Biopharmaceutics, Pharmacokinetics and Pharmacodynamics. <i>Interdisciplinary Applied Mathematics</i> , 2016 ,	0.7	17
89	Establishment of a mouse model for amiodarone-induced liver injury and analyses of its hepatotoxic mechanism. <i>Journal of Applied Toxicology</i> , 2016 , 36, 35-47	4.1	16
88	Interaction between amiodarone and hepatitis-C virus nucleotide inhibitors in human induced pluripotent stem cell-derived cardiomyocytes and HEK-293 Cav1.2 over-expressing cells. <i>Toxicology and Applied Pharmacology</i> , 2016 , 308, 66-76	4.6	13
87	Quantitative Prediction of Drug-Drug Interactions Involving Inhibitory Metabolites in Drug Development: How Can Physiologically Based Pharmacokinetic Modeling Help?. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2016 , 5, 505-515	4.5	13
86	Effect of grapefruit juice on amiodarone induced nephrotoxicity in albino rats. <i>Toxicology and Industrial Health</i> , 2016 , 32, 68-75	1.8	5
85	Association between N-desethylamiodarone/amiodarone ratio and amiodarone-induced thyroid dysfunction. <i>European Journal of Clinical Pharmacology</i> , 2017 , 73, 289-296	2.8	7
84	Class III antiarrhythmic drugs amiodarone and dronedarone impair K _v 2.1 backward trafficking. <i>Journal of Cellular and Molecular Medicine</i> , 2017 , 21, 2514-2523	5.6	9
83	Management of ventricular tachycardia storm in patients with structural heart disease. <i>World Journal of Cardiology</i> , 2017 , 9, 521-530	2.1	24
82	Analysis of computed tomography density of liver before and after amiodarone administration. <i>Japanese Journal of Radiology</i> , 2018 , 36, 340-344	2.9	3
81	A pharmacokinetic model for amiodarone in infants developed from an opportunistic sampling trial and published literature data. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2018 , 45, 419-430	2.7	5
80	Association between Serum Amiodarone and N-Desethylamiodarone Concentrations and Development of Thyroid Dysfunction. <i>Clinical Drug Investigation</i> , 2018 , 38, 39-48	3.2	5
79	Fractional calculus in pharmacokinetics. <i>Journal of Pharmacokinetics and Pharmacodynamics</i> , 2018 , 45, 107-125	2.7	41
78	Relevance of Half-Life in Drug Design. <i>Journal of Medicinal Chemistry</i> , 2018 , 61, 4273-4282	8.3	49

77	[Challenges in the management of amiodarone-induced thyrotoxicosis]. <i>Presse Medicale</i> , 2018 , 47, 746-756	3
76	Amiodarone's major metabolite, desethylamiodarone, induces apoptosis in human cervical cancer cells. <i>Canadian Journal of Physiology and Pharmacology</i> , 2018 , 96, 1004-1011	2.4 1
75	Drugs and Other Substances Interfering with Thyroid Function. <i>Endocrinology</i> , 2018 , 733-761	0.1 3
74	Interaction between warfarin and short-term intravenous amiodarone in intensive care unit patients after cardiac surgery. <i>Journal of Pharmaceutical Health Care and Sciences</i> , 2018 , 4, 13	1.8 3
73	Mechanisms and Drug Development in Atrial Fibrillation. <i>Pharmacological Reviews</i> , 2018 , 70, 505-525	22.5 38
72	[Amiodarone-induced optic neuropathy: A rare side effect]. <i>Revue De Medecine Interne</i> , 2019 , 40, 826-830.	0.1 1
71	Anti-arrhythmic drug therapy in implantable cardioverter-defibrillator recipients. <i>Pharmacological Research</i> , 2019 , 143, 133-142	10.2 1
70	Prediction of human pharmacokinetics of long half-life compounds using chimeric mice with humanised liver. <i>Xenobiotica</i> , 2019 , 49, 1379-1387	2 11
69	Maternal monitoring and safety considerations during antiarrhythmic treatment for fetal supraventricular tachycardia. <i>Obstetric Medicine</i> , 2019 , 12, 66-75	1.5 9
68	Time-to-onset analysis of amiodarone-associated thyroid dysfunction. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2020 , 45, 65-71	2.2 4
67	Amiodarone's major metabolite, desethylamiodarone inhibits proliferation of B16-F10 melanoma cells and limits lung metastasis formation in an in vivo experimental model. <i>PLoS ONE</i> , 2020 , 15, e0239088	2.7 0
66	Involvement of Mitochondrial Mechanisms in the Cytostatic Effect of Desethylamiodarone in B16F10 Melanoma Cells. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3 0
65	A comparison of thyroidal protection by stable iodine or perchlorate in the case of acute or prolonged radioiodine exposure. <i>Archives of Toxicology</i> , 2020 , 94, 3231-3247	5.8 4
64	Filovirus Antiviral Activity of Cationic Amphiphilic Drugs Is Associated with Lipophilicity and Ability To Induce Phospholipidosis. <i>Antimicrobial Agents and Chemotherapy</i> , 2020 , 64,	5.9 8
63	Amiodarone: A Comprehensive Guide for Clinicians. <i>American Journal of Cardiovascular Drugs</i> , 2020 , 20, 549-558	4 10
62	Draft of the federal clinical recommendations for diagnosis and treatment of amiodarone-induced thyroid dysfunction. <i>Klinička i Eksperimentalna Endokrinologija</i> , 2021 , 16, 12-24	0.8 2
61	Estimation of the Release of Amiodarone From the Pharmacokinetics of Its Active Metabolite and Correlation With Its Release. <i>Frontiers in Pharmacology</i> , 2020 , 11, 621667	5.6 0
60	Pharmacokinetic Disposition of Amiodarone When Given with an Intralipid Rescue Strategy. <i>Pharmaceutics</i> , 2021 , 13,	6.4

59	Numerical simulation of a two-compartmental fractional model in pharmacokinetics and parameters estimation. <i>Mathematical Methods in the Applied Sciences</i> , 2021 , 44, 11526-11536	2.3	0
58	Investigation of the arcane inhibition of human organic anion transporter 3 by benzofuran antiarrhythmic agents. <i>Drug Metabolism and Pharmacokinetics</i> , 2021 , 38, 100390	2.2	1
57	Metabolite Testing in Drug Development. 2011 , 131-143		2
56	Toxicology of Perchlorate. 2000 , 15-29		20
55	The Defibrillation Threshold. <i>Developments in Cardiovascular Medicine</i> , 1996 , 89-129		11
54	Heart Drugs and Influences on TH Metabolism. 2020 , 311-325		2
53	Amiodarone: Electropharmacologic Properties. <i>Handbook of Experimental Pharmacology</i> , 1989 , 335-364	3.2	3
52	Clinical and Pharmacologic Characterization and Treatment of Potentially Malignant Arrhythmias of Chronic Chagasic Cardiomyopathy. <i>Handbook of Experimental Pharmacology</i> , 1989 , 601-620	3.2	3
51	Testing and Programming of Implantable Defibrillator Functions at Implantation. 2007 , 531-557		4
50	Pulmonary and Pleural Complications of Cardiac Disease. <i>Clinics in Chest Medicine</i> , 1989 , 10, 545-592	5.3	31
49	Clinical Aspects of Amiodarone Pulmonary Toxicity. <i>Clinics in Chest Medicine</i> , 1990 , 11, 119-129	5.3	32
48	Mechanisms of Amiodarone Pulmonary Toxicity. <i>Clinics in Chest Medicine</i> , 1990 , 11, 131-138	5.3	44
47	Interaction between amiodarone and lidocaine. <i>Journal of Cardiovascular Pharmacology</i> , 1996 , 28, 533-9	3.1	21
46	Hemodynamic and antiadrenergic effects of dronedarone and amiodarone in animals with a healed myocardial infarction. <i>Journal of Cardiovascular Pharmacology</i> , 2000 , 36, 376-83	3.1	32
45	Part IV: Class II, Class III, and Class IV Antiarrhythmic Drugs, Comparative Efficacy of Drugs, and Effect of Drugs on Mortality ? A Review of Their Pharmacokinetics, Efficacy, and Toxicity. <i>Journal of Cardiovascular Electrophysiology</i> , 1988 , 2, 55-87	2.7	3
44	Pharmacokinetics and regional electrophysiological effects of intracoronary amiodarone administration. <i>Circulation</i> , 1995 , 91, 451-61	16.7	19
43	Antagonism of thyroid hormone action by amiodarone in rat pituitary tumor cells. <i>Journal of Clinical Investigation</i> , 1989 , 83, 306-13	15.9	57
42	Adverse reactions of Amiodarone. <i>Journal of Geriatric Cardiology</i> , 2019 , 16, 552-566	1.7	17

41	Desethylamiodarone-A metabolite of amiodarone-Induces apoptosis on T24 human bladder cancer cells via multiple pathways. <i>PLoS ONE</i> , 2017 , 12, e0189470	3.7	13
40	Therapeutic monitoring of amiodarone: pharmacokinetics and evaluation of the relationship between effect and dose/concentration. <i>Biomedical Papers of the Medical Faculty of the University Palacky&#x0301;, Olomouc, Czechoslovakia</i> , 2017 , 161, 134-143	1.7	12
39	Antiarrhythmic agents*. <i>Medical Journal of Australia</i> , 1984 , 141, 718-723	4	1
38	Therapie kardiovaskulärer Erkrankungen. 2000 , 123-265		
37	Therapie kardiovaskulärer Erkrankungen. 2003 , 157-304		
36	Antiarrhythmika: Medikamentöse Therapie von Herzrhythmusstörungen. 2004 , 831-846		
35	Cardiac Arrest and Cardiopulmonary Resuscitation. 2006 , 333-365		
34	Cardiac dysrhythmias during donor care. <i>Progress in Transplantation</i> , 2006 , 16, 74-81	1.1	
33	Antiarrhythmic drugs. 2011 , 224-241		
32	Erkrankungen des Herzens und der GefäÙ. 1985 , 393-446		
31	Pharmacology of Cardiac Drugs. 1985 , 239-288		
30	Effect of Age on the Clinical Pharmacokinetics of Antiarrhythmic Drugs. 1986 , 207-247		
29	The Pharmacology of Antiarrhythmic Drugs. 1986 , 241-268		
28	Pharmacokinetics and Patient Care. 1986 , 131-160		
27	Pharmacokinetics of antiarrhythmic drugs. <i>Developments in Cardiovascular Medicine</i> , 1987 , 329-339		
26	The Determination of Plasma Amiodarone and Desethylamiodarone by HPLC. 1988 , 185-191		
25	Chronic Drug-Induced Hepatotoxicity: Clinical Aspects. 1989 , 243-251		
24	Thyroid Disease. 1989 , 37-61		

23	Practical Applications of Therapeutic Drug Monitoring: The impact of technological developments. 1989 , 93-102		
22	The oral antiarrhythmic drugs. <i>Progress in Drug Research Fortschritte Der Arzneimittelforschung Progres Des Recherches Pharmaceutiques</i> , 1990 , 35, 151-247		2
21	Pharmakologie der Antiarrhythmika. 1991 , 1-9		
20	Herzchirurgie. 1995 , 605-667		
19	Pharmacologic Therapy of Arrhythmias. <i>Developments in Cardiovascular Medicine</i> , 1999 , 559-599		
18	Drugs and Other Substances Interfering with Thyroid Function. <i>Endocrinology</i> , 2018 , 1-29	0.1	
17	HYPOTHYROIDISM SECONDARY TO AMIODARONE USE. <i>Konuralp Tip Dergisi</i> , 248-250		0
16	Low-dose Amiodarone Is Safe: A Systematic Review and Meta-analysis. <i>Journal of Innovations in Cardiac Rhythm Management</i> , 2020 , 11, 4054-4061	1.1	1
15	Therapie kardiovaskulärer Erkrankungen. 171-307		
14	Diagnostik und Therapie der Amiodaron-induzierten Hyperthyreose.		
13	Newer Cardiac Agents: Antiarrhythmics and Antianginal Agents. <i>Clinics in Laboratory Medicine</i> , 1987 , 7, 567-585	2.1	
12	The clinical spectrum of amiodarone-associated optic neuropathy. <i>Journal of the National Medical Association</i> , 2004 , 96, 1477-91	2.3	25
11	The letter by Mullier in response to our article. <i>Cardiovascular Journal of Africa</i> , 2012 , 23, 273	0.7	
10	Increased serum amiodarone concentration in hypertriglyceridemic patients: Effects of drug distribution to serum lipoproteins. <i>Clinical and Translational Science</i> , 2021 ,	4.9	1
9	Screening for drugs potentially interfering with MCT8-mediated T transport in vitro identifies dexamethasone and some commonly used drugs as inhibitors of MCT8 activity. <i>Journal of Endocrinological Investigation</i> , 2021 , 1	5.2	0
8	Fractional Kinetics Analysis of Pharmacological Models of Drug Distribution and Accumulation: Exact Solutions Type Multivariate Mittag-Leffler Functions. <i>SSRN Electronic Journal</i> ,	1	
7	Analysis of the Variability of the Pharmacokinetics of the Long Half-Life Drug Amiodarone in Bioequivalence Studies. <i>Timisoara Medical Journal</i> , 2021 , 2020, 1	0	
6	Involvement of Mitochondrial Mechanisms and Cyclooxygenase-2 Activation in the Effect of Desethylamiodarone on 4T1 Triple-Negative Breast Cancer Line.. <i>International Journal of Molecular Sciences</i> , 2022 , 23,	6.3	1

- 5 New antiarrhythmic drugs in pediatric use: amiodarone. *Pediatric Cardiology*, **1994**, 15, 132-8 2.1 11
- 4 Part 10: Pediatric Advanced Life Support. *Circulation*, **2000**, 102, 16.7 1
- 3 Population Pharmacokinetic Model of Amiodarone and α -Desethylamiodarone Focusing on Glucocorticoid and Inflammation. *Biological and Pharmaceutical Bulletin*, **2022**, 45, 948-954 2.3
- 2 An updated approach to the diagnosis and management of amiodarone-induced thyrotoxicosis. **2023**, 24, 135-141 0
- 1 Amiodarone overdose and its management. **1989**, 43, 184-186 0